|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
|
EP3143134B1
(en)
|
2014-05-15 |
2020-10-28 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
LT3182996T
(lt)
*
|
2014-08-22 |
2023-03-10 |
Celgene Corporation |
Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
|
|
EP3227441B1
(en)
|
2014-12-01 |
2021-06-30 |
Summa Health |
Camkk1 as a novel regenerative therapeutic
|
|
US10034901B2
(en)
|
2015-01-22 |
2018-07-31 |
University Of Massachusetts |
Cancer immunotherapy
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
WO2021178701A1
(en)
*
|
2020-03-05 |
2021-09-10 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of modified lymphocyte aggregates
|
|
WO2021042072A1
(en)
*
|
2019-09-01 |
2021-03-04 |
Exuma Biotech Corp. |
Methods and compositions for the modification and delivery of lymphocytes
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
JP7373991B2
(ja)
*
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
KR20190114966A
(ko)
*
|
2016-12-09 |
2019-10-10 |
온키뮨 리미티드 |
조작된 자연 살해 세포 및 이의 용도
|
|
CN108277205B
(zh)
*
|
2016-12-30 |
2022-12-20 |
四川大学 |
表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
SG11201908492PA
(en)
|
2017-03-27 |
2019-10-30 |
Nat Univ Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
US12129487B2
(en)
*
|
2017-03-27 |
2024-10-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to obtain lymphoid progenitors
|
|
EP3601537A4
(en)
|
2017-03-27 |
2021-01-13 |
National University of Singapore |
STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
|
|
KR20240132124A
(ko)
|
2017-05-25 |
2024-09-02 |
유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 |
천연 살해 세포에 의해 사멸하는 종양 세포를 감작시키기 위한 신규한 종양용해 바이러스
|
|
TWI676483B
(zh)
*
|
2017-08-06 |
2019-11-11 |
強普生技股份有限公司 |
醫藥套組及其用途
|
|
CA3077325A1
(en)
*
|
2017-09-28 |
2019-04-04 |
Celularity Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
JP7239567B2
(ja)
|
2017-10-02 |
2023-03-14 |
ガミダ セル リミテッド |
Ｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
|
|
KR20200076732A
(ko)
*
|
2017-11-03 |
2020-06-29 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd38-지시된 키메라 항원 수용체 작제물
|
|
JP2021505637A
(ja)
|
2017-12-12 |
2021-02-18 |
マクロジェニクス，インコーポレーテッド |
二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
SG10201900072VA
(en)
*
|
2018-01-05 |
2019-08-27 |
Gnt Biotech & Medicals Corp |
A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
US11814623B2
(en)
|
2018-01-30 |
2023-11-14 |
University Of Massachusetts |
Methods of treating a wound using epigenetic regulation
|
|
EP3746095A4
(en)
|
2018-02-01 |
2021-04-21 |
Nkmax Co., Ltd. |
Method of producing natural killer cells and composition for treating cancer
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
US20190284288A1
(en)
*
|
2018-03-19 |
2019-09-19 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
|
KR20200138741A
(ko)
|
2018-04-02 |
2020-12-10 |
내셔널 유니버시티 오브 싱가포르 |
면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
|
|
EP3781182A4
(en)
|
2018-04-18 |
2021-11-17 |
Summa Health |
COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA
|
|
WO2019200586A1
(en)
*
|
2018-04-19 |
2019-10-24 |
The Chinese University Of Hong Kong |
Modified nk cells and uses thereof
|
|
GB201807050D0
(en)
*
|
2018-04-30 |
2018-06-13 |
Cellprotect Nordic Pharmaceuticals Ab |
Medical uses
|
|
KR102373502B1
(ko)
|
2018-05-14 |
2022-03-11 |
주식회사 금호에이치티 |
골수유래억제세포 관련 질환의 예방 및 치료 용도
|
|
KR102069704B1
(ko)
*
|
2018-05-16 |
2020-01-23 |
고려대학교 산학협력단 |
Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
|
|
CN112204133B
(zh)
*
|
2018-05-30 |
2024-04-19 |
格雷克斯迪姆医疗私人有限公司 |
Car nk细胞
|
|
EP3806894A4
(en)
|
2018-06-12 |
2022-06-08 |
Promab Biotechnologies, Inc. |
PLAP-CAR EFFECTOR CELLS
|
|
CN108815186A
(zh)
*
|
2018-06-14 |
2018-11-16 |
上海鸣大生物科技有限公司 |
一种治疗hpv持续感染引起疾病的药物及制备方法与应用
|
|
JP7560882B2
(ja)
|
2018-08-29 |
2024-10-03 |
ナショナル ユニヴァーシティー オブ シンガポール |
遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
|
|
EP3846829A4
(en)
*
|
2018-09-05 |
2022-09-14 |
Arizona Board of Regents on behalf of Arizona State University |
ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
|
|
CA3114707A1
(en)
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
AU2019372673A1
(en)
|
2018-11-01 |
2021-05-27 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for T cell engineering
|
|
WO2020113234A1
(en)
*
|
2018-11-30 |
2020-06-04 |
Celularity, Inc. |
Placenta-derived allogeneic car-t cells and uses thereof
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
SG11202110261QA
(en)
*
|
2019-03-21 |
2021-10-28 |
Gamida Cell Ltd |
Expanded nk cell fractions for transplantation in combination therapy
|
|
SG11202111130SA
(en)
|
2019-04-30 |
2021-11-29 |
Senti Biosciences Inc |
Chimeric receptors and methods of use thereof
|
|
WO2021016621A1
(en)
*
|
2019-07-25 |
2021-01-28 |
Celularity Inc. |
Populations of natural killer cells comprising a cd38 chimeric antigen receptor
|
|
MX2022004323A
(es)
*
|
2019-10-10 |
2022-08-02 |
Univ Arizona State |
Virus oncoliticos que expresan captadores multiespecificos de celulas inmunitarias.
|
|
JP2023503982A
(ja)
*
|
2019-11-27 |
2023-02-01 |
デヴェラ セラピューティクス インコーポレイテッド |
造血幹および前駆細胞を培養するための組成物および方法
|
|
KR20220107233A
(ko)
*
|
2019-11-28 |
2022-08-02 |
글리코스템 떼라퓨틱스 비.브이. |
Car-nk 세포의 수득 방법
|
|
US20230355671A1
(en)
*
|
2020-03-18 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases
|
|
US20240000937A1
(en)
*
|
2020-09-22 |
2024-01-04 |
World Biotech Regenerative Medical Group Limited |
Methods and compositions of car-expressing natural killer cells with bispecific antigen-binding molecules as cancer therapeutic agents
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN113398264B
(zh)
*
|
2021-08-06 |
2022-04-29 |
朱有建 |
Nk细胞及其组合物在治疗癌症中的用途
|
|
US20240335472A1
(en)
*
|
2021-08-10 |
2024-10-10 |
Gamida Cell Ltd. |
Anti-her2 car nk cells, methods of their production and uses thereof
|
|
CN113577267B
(zh)
*
|
2021-09-06 |
2022-04-08 |
江西北正干细胞生物科技有限公司 |
Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
|
|
WO2023038037A1
(ja)
*
|
2021-09-08 |
2023-03-16 |
株式会社ガイアバイオメディシン |
細胞の処理方法
|
|
EP4180049A1
(en)
*
|
2021-11-16 |
2023-05-17 |
Ostravska univerzita |
Therapeutic composition for cancer treatment
|
|
CN114058584B
(zh)
*
|
2022-01-07 |
2022-07-01 |
山东省齐鲁干细胞工程有限公司 |
一种临床用自然杀伤细胞的制备方法
|
|
CN115927169B
(zh)
*
|
2022-10-11 |
2023-08-11 |
再造再生医学科技(杭州)有限公司 |
用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法
|
|
CN119082021B
(zh)
*
|
2024-09-30 |
2025-03-28 |
广东壹加再生医学研究院有限公司 |
一种增强型nk细胞及其制备方法
|